Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of lenalidomide with or without bortezomib after T-cell depleted non-myeloablative allogeneic stem cell transplantation in relapsed multiple myeloma
2010-018494-37Phase 2Suspended
- Sponsor
- HOVON
- Start
- Aug 2010
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in multiple myeloma (MM) comparing Lenalidomide consolidation with Lenalidomide + bortezomib consolidation (2 arms). Primary endpoint: Failure free duration at 9 months post-transplant. Started Aug 2010; status: suspended.
02
Drugs
lenalidomidebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2010-018494-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018494-37.